Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02745678 · ClinicalTrials.gov registry record · Phase 1
Localized Therapeutics for the Treatment of Gastrointestinal Disorders II
A Phase 1 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT02745678: Completed Phase 1 study, sponsored by Stanford University.
NCT02745678 is a Phase 1 study that has completed, run by Stanford University. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02745678, a Phase 1 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate a novel thermosensitive topical gel formulation for the treatment of inflammatory bowel disease (IBD), specifically ulcerative colitis.
Interventions
- DRUG Thermosensitive gel rectal formulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2016-01 |
| Est. Completion | 2017-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02745678
The ClinicalTrials.gov registry entry for NCT02745678 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Thermosensitive gel rectal formulation is the first listed.
NCT02745678 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02745678 about?
NCT02745678 is a clinical study titled "Localized Therapeutics for the Treatment of Gastrointestinal Disorders II". The purpose of this study is to investigate a novel thermosensitive topical gel formulation for the treatment of inflammatory bowel disease (IBD), specifically ulcerative colitis.
What is the current status of trial NCT02745678?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2016-01. Estimated completion is 2017-11.
What interventions are being tested in trial NCT02745678?
The interventions under investigation include: Thermosensitive gel rectal formulation (DRUG).
Who is sponsoring clinical trial NCT02745678?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.